Last reviewed · How we verify
CYP 450 Substrates
CYP 450 substrates inhibit the activity of the cytochrome P450 enzyme system.
At a glance
| Generic name | CYP 450 Substrates |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | CYP 450 substrates |
| Target | Cytochrome P450 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
This mechanism is used to describe drugs that are metabolized by the CYP 450 enzyme system, which can be inhibited by various substances, leading to increased drug levels and potential toxicity.
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (PHASE2)
- The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |